CA3237801A1 - Relaxin-2 fusion protein analogs and methods of using same - Google Patents

Relaxin-2 fusion protein analogs and methods of using same Download PDF

Info

Publication number
CA3237801A1
CA3237801A1 CA3237801A CA3237801A CA3237801A1 CA 3237801 A1 CA3237801 A1 CA 3237801A1 CA 3237801 A CA3237801 A CA 3237801A CA 3237801 A CA3237801 A CA 3237801A CA 3237801 A1 CA3237801 A1 CA 3237801A1
Authority
CA
Canada
Prior art keywords
amino acid
seq
acid sequence
peptide comprises
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3237801A
Other languages
English (en)
French (fr)
Inventor
John Diener
Andrew KRUSE
Franz GRUSWITZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tectonic Therapeutic Inc
Original Assignee
Tectonic Therapeutic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tectonic Therapeutic Inc filed Critical Tectonic Therapeutic Inc
Publication of CA3237801A1 publication Critical patent/CA3237801A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CA3237801A 2021-11-11 2022-11-11 Relaxin-2 fusion protein analogs and methods of using same Pending CA3237801A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163263917P 2021-11-11 2021-11-11
US63/263,917 2021-11-11
PCT/US2022/079681 WO2023086913A2 (en) 2021-11-11 2022-11-11 Relaxin-2 fusion protein analogs and methods of using same

Publications (1)

Publication Number Publication Date
CA3237801A1 true CA3237801A1 (en) 2023-05-19

Family

ID=86336636

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3237801A Pending CA3237801A1 (en) 2021-11-11 2022-11-11 Relaxin-2 fusion protein analogs and methods of using same

Country Status (10)

Country Link
US (1) US12509497B2 (https=)
EP (1) EP4429694A4 (https=)
JP (1) JP2024543455A (https=)
KR (1) KR20240110824A (https=)
CN (1) CN118510536A (https=)
AU (1) AU2022388751A1 (https=)
CA (1) CA3237801A1 (https=)
IL (1) IL312731A (https=)
MX (1) MX2024005654A (https=)
WO (1) WO2023086913A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118510536A (zh) 2021-11-11 2024-08-16 泰克托尼治疗股份有限公司 松弛素-2融合蛋白类似物及其使用方法
AU2024270919A1 (en) 2023-05-18 2026-01-15 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4835251A (en) 1986-06-23 1989-05-30 Genetech, Inc. Method of chain combination
WO2007115414A1 (en) 2006-04-11 2007-10-18 University Of Guelph Modified h2 relaxin for tumor suppression
WO2009055854A1 (en) 2007-10-30 2009-05-07 Howard Florey Institute Of Experimental Physiology And Medicine Chimeric relaxin polypeptides comprising an a and b chain derived from different relaxin family peptides
WO2010105081A1 (en) 2009-03-13 2010-09-16 Medtronic, Inc. Method of treating heart failure
US8389475B2 (en) 2009-08-10 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Relaxin analogs
US20110243943A1 (en) 2010-04-02 2011-10-06 Athena Discovery, Inc. Treatment using relaxin-fusion proteins with extended in vivo half-lives
EA030886B1 (ru) 2010-08-17 2018-10-31 Амбркс, Инк. Модифицированные полипептиды релаксина, содержащие некодируемую в природе аминокислоту, связанную с полимером, и их применение
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
EP2614076A4 (en) 2010-09-08 2014-03-05 Florey Howard Inst CHANGED RELAXIN POLYPEPTIDES
GB201110833D0 (en) 2011-06-24 2011-08-10 Bold Venture Llc Compositions
RU2014103288A (ru) 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
KR20140039257A (ko) 2011-07-08 2014-04-01 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신을 방출하는 융합 단백질 및 이의 용도
JP6276690B2 (ja) 2011-08-04 2018-02-07 ファリス バイオテック ゲーエムベーハー ヒトリラキシン−２を調製する方法
EP2630964A1 (en) 2012-02-22 2013-08-28 Immundiagnostik AG Method and medicament for treating patients in risk of prediabetes and type-2 diabetes
WO2013177529A1 (en) 2012-05-24 2013-11-28 Angion Biomedica Corp. Relaxin-like compounds and uses thereof
WO2014040008A1 (en) 2012-09-10 2014-03-13 Angion Biomedica Corp. Relaxin-like peptides and uses thereof
US9381231B2 (en) 2012-10-09 2016-07-05 University Of Florida Research Foundation, Inc. Use of relaxin to restore maternal physiology in pregnancies conceived by assisted reproductive technologies
US20150232526A1 (en) 2012-10-10 2015-08-20 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Use of relaxin to treat atrial fibrillation
US9005630B2 (en) 2012-11-01 2015-04-14 Veterinaerinstituttet Fusion proteins for the treatment of allergic diseases
US9907833B2 (en) 2013-07-25 2018-03-06 University Of Florida Research Foundation, Incorporated Use of relaxin to treat placental syndromes
JP6822839B2 (ja) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
KR20160055940A (ko) 2013-09-24 2016-05-18 엘라스타겐 피티와이 리미티드 단백질 추출 방법
EP3068891A1 (en) 2013-11-13 2016-09-21 Aequus Biopharma Inc. Engineered glycoproteins and uses thereof
RU2711322C1 (ru) * 2013-12-20 2020-01-16 Ф. Хоффманн-Ля Рош Аг Улучшенные способы получения рекомбинантного полипептида
EP3131925B1 (en) 2014-04-17 2020-02-19 The Florey Institute of Neuroscience and Mental Health Modified relaxin b chain peptides
EP2946788A1 (en) 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
WO2016144968A1 (en) 2015-03-09 2016-09-15 University Of Washington Relaxin therapy for disorders of the diaphragm
GB201516068D0 (en) 2015-09-10 2015-10-28 Biomed Ltd B V Novel therapy
PT3387019T (pt) 2015-12-09 2022-01-14 Scripps Research Inst Proteínas de fusão de imunoglobulina de relaxina e métodos de uso
IL263079B2 (en) 2016-05-18 2024-05-01 Modernatx Inc Polynucleotides encoding relaxin
WO2018023170A1 (en) 2016-08-04 2018-02-08 Hudson Institute of Medical Research A method of treatment
WO2018068047A1 (en) 2016-10-07 2018-04-12 Beth Israel Deaconess Medical Center, Inc. Compositions comprising relaxin and methods of use thereof
EP3574004A1 (en) * 2017-01-25 2019-12-04 Medimmune, LLC Relaxin fusion polypeptides and uses thereof
PE20191716A1 (es) * 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
WO2019149781A1 (en) 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
TW201934572A (zh) 2018-01-31 2019-09-01 法商賽諾菲公司 經修飾之鬆弛素ｂ鏈胜肽及其治療用途
NZ766762A (en) 2018-01-31 2026-03-27 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
WO2021094626A1 (en) 2019-11-16 2021-05-20 Relaxera Pharmazeutische Gmbh & Co. Kg Medical composition for treating cardiac wasting and cachexia
CN115768801A (zh) * 2020-05-08 2023-03-07 哈佛学院院长等 工程化松弛素及其使用方法
JP2023526512A (ja) 2020-05-22 2023-06-21 トラスティーズ オブ ボストン ユニバーシティ 線維化疾患を処置するための方法および組成物
US20210380655A1 (en) 2020-06-02 2021-12-09 Trustees Of Boston University Production of soluble relaxin and relaxin analogs
CA3186143A1 (en) 2020-06-17 2021-12-23 Medimmune Limited Heterodimeric relaxin fusions and uses thereof
CN114075276A (zh) 2020-08-17 2022-02-22 成都奥达生物科技有限公司 一种长效松弛素2类似物
CN113577289A (zh) 2021-01-11 2021-11-02 张莉 Rxfp1/3抑制剂在制备预防或治疗青少年特发性脊柱侧凸疾病的药物中的用途
AU2022334113A1 (en) 2021-08-23 2024-03-14 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions
CA3230581A1 (en) 2021-09-14 2023-03-23 Bellylabs Oy Assay method for relaxin
WO2023056044A1 (en) 2021-10-01 2023-04-06 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
CN118510536A (zh) 2021-11-11 2024-08-16 泰克托尼治疗股份有限公司 松弛素-2融合蛋白类似物及其使用方法
AU2022410335A1 (en) 2021-12-15 2024-07-18 Medimmune Limited Treatment using heterodimeric relaxin fusions
CA3252059A1 (en) 2022-05-07 2025-07-07 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Relaxin fusion protein or analogue and its medical use
JP2025528469A (ja) 2022-08-31 2025-08-28 リラクセラ ファルマツォイティッシュ ゲゼルシャフト エムベーハー ウント コー． カーゲー 免疫抑制薬及び処置方法
AU2024270919A1 (en) * 2023-05-18 2026-01-15 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same

Also Published As

Publication number Publication date
WO2023086913A3 (en) 2023-06-22
JP2024543455A (ja) 2024-11-21
KR20240110824A (ko) 2024-07-16
WO2023086913A2 (en) 2023-05-19
CN118510536A (zh) 2024-08-16
IL312731A (en) 2024-07-01
US12509497B2 (en) 2025-12-30
MX2024005654A (es) 2024-09-11
EP4429694A2 (en) 2024-09-18
EP4429694A4 (en) 2025-10-01
AU2022388751A1 (en) 2024-05-30
US20230340058A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
KR20200095436A (ko) 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체
KR20170044115A (ko) 동일한 진핵생물 세포 생산 숙주 내 조건부 활성 생체 단백질의 발견 및 제조
CA3237801A1 (en) Relaxin-2 fusion protein analogs and methods of using same
JP2013519392A (ja) Ｈｓａ関連組成物および使用方法
KR20180002855A (ko) 항암 융합 폴리펩타이드
CN111712573B (zh) 针对骨硬化蛋白的适体及其用途
EP3110434B1 (en) Uti fusion proteins
US20220089786A1 (en) Treatment of sjogren's disease with nuclease fusion proteins
US12264188B2 (en) Relaxin-2 fusion proteins
JP2023055875A (ja) Ｈｉｖ融合体を標的とするポリペプチド
JP2019535645A (ja) ラフォラ病の処置のための方法及び組成物
CN110536899B (zh) 对胰岛素受体具有降低的亲和力的胰岛素类似物复合物及其用途
TW201908337A (zh) 活性型ｍｍｐ－９結合肽
GB2526898A (en) Biological materials and therapeutic uses thereof
CN113396158A (zh) Lpl-gpihbp1融合多肽
CN112423779B (zh) 用于治疗色素性视网膜炎的肽
US20260085125A1 (en) Apelin receptor binding polypeptides and methods
KR102859616B1 (ko) 개선된 fix 융합 단백질 및 접합체 및 이의 용도
WO2005090570A1 (en) Therapeutic compositions and methods for treating diseases that involve angiogenesis
WO2024148295A2 (en) Smagp fusion molecules and methods of use thereof
TW202146429A (zh) Ｃ４結合蛋白之ｃ端片段與血管生成素－１之類纖維蛋白原結構域之間之嵌合融合作為治療血管疾病之血管生成素模擬物及ｔｉｅ２促效劑
CA3168534A1 (en) Method of enhancing aqueous humor outflow and reducing intraocular pressure
KR20210082189A (ko) Glp-2 융합 폴리펩티드 및 위장 병태를 치료 및 예방하기 위한 용도
HK1234103A1 (en) Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts

Legal Events

Date Code Title Description
P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20241024

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241101

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241101

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241101

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241115

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20241125

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241125

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250321

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251107

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251107

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED

Effective date: 20260330